Cipla Medpro enters marketing tie up with Teva Pharma for South African market
Medpro Pharmaceutica (Pty) Ltd, a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa, has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd, the largest generic pharma manufacturer in the world with a presence in about 60 countries and approximately 45, 000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.
The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa.
Paul Miller, CEO of Cipla Medpro, said, “This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines.”
The collaboration with Teva in South Africa will focus on the therapeutic areas like oncology, central nervous system, women's health, cardiovascular, ophthalmology and other specialty products.
Subhanu Saxena, managing director and global chief executive officer of Cipla Ltd, said, “Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans.”